Pathophysiologic mechanisms in atopic dermatitis

Seminars in Cutaneous Medicine and Surgery

Volumn 20, Issue 4, 2001, Pages 217-225

  Boguniewicz, M ^a   Leung, D Y M ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; CALCINEURIN INHIBITOR; CORTICOSTEROID; IMMUNOLOGIC FACTOR; TACROLIMUS;

ARTICLE; ASTHMA; ATOPIC DERMATITIS; CHRONIC INFLAMMATION; ENVIRONMENTAL FACTOR; GENE CONTROL; HEREDITY; HUMAN; LANGERHANS CELL; LYMPHOCYTE HOMING; PATHOPHYSIOLOGY; RHINOCONJUNCTIVITIS;

EID: 0035211713     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1053/sder.2001.29379     Document Type: Article

References (73)

1. Atopic dermatitis
2. Quality of life in atopic dermatitis
3. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood
4. Shifts in interleukin-4 and interferon-γ production by T cells of patients with elevated serum IgE levels and the modulatory effects of these lymphokines on spontaneous IgE synthesis
5. IgE regulation and roles in asthma pathogenesis
6. Enhanced expression of B7.2 (CD86) in patients with atopic dermatitis: A potential role in the modulation of IgE synthesis
7. Immunoglobulin E and immunoglobulin G subclass distribution in vivo and relationship to in vitro generation of interferon-gamma and neopterin in patients with severe atopic dermatitis
8. Correlation of house dust mite-specific lymphocyte proliferation with IL-5 production, eosinophilia, and the severity of symptoms in infants with atopic dermatitis
9. Unique profile of IL-4 and IFN-gamma production by peripheral blood mononuclear cells in infants with atopic dermatitis
10. Mechanisms of eosinophil-associated inflammation
11. Chemokines and allergic disease
12. Granulocyte macrophage colony-stimulating factor contributes to enhanced monocyte survival in chronic atopic dermatitis
13. Atopic dermatitis: New insights and opportunities for therapeutic intervention
14. Lymphocyte homing and homeostasis
15. Circulating allergen-reactive T cells from patients with atopic dermatitis and allergic contact dermatitis express the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen
16. Skin-homing, CLA+ memory T cells are activated in atopic dermatitis and regulate IgE by an IL-13-dominated cytokine pattern: IgG4 counterregulation by CLA-memory T cells
17. Skin homing (cutaneous lymphocyte-associated antigen-positive) CD8+ T cells respond to superantigen and contribute to eosinophilia and IgE production in atopic dermatitis
18. CTACK a skinassociated chemokine that preferentially attracts skin-homing memory T cells
19. Characterization of the mononuclear cell infiltrate in atopic dermatitis using monoclonal antibodies
20. The presence of IgE molecules on epidermal Langerhans cells in patients with atopic dermatitis
21. Dermal eosinophils in atopic dermatitis undergo cytolytic degeneration
22. Urinary, eosinophil protein X and serum eosinophil cationic protein in infants and young children with atopic dermatitis: Correlation with disease activity
23. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis
24. In vivo expression of IL-12 and IL-13 in atopic dermatitis
25. A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis
26. IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family
27. T cells and T cellderived cytokines as pathogenic factors in the nonallergic form of atopic dermatitis
28. T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis
29. In vivo expression of cytokine receptor mRNA in atopic dermatitis
30. Evidence for increased expression of eotaxin and monocyte chemotactic protein-4 in atopic dermatitis
31. Enhanced expression of eotaxin and CCR3 in atopic dermatitis
32. Association of increased CD4+ T-cell infiltration with increased IL-16 gene expression in atopic dermatitis
33. Chemical mediators in atopic dermatitis: Involvement of leukotriene B4 released by a type 1 allergic reaction in the pathogenesis of atopic dermatitis
34. Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis
35. Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens
36. Staphylococcal toxic shock syndrome toxin-1 inhibits monocyte apoptosis
37. Linkage and association of an interleukin 4 gene polymorphism with atopic dermatitis in Japanese families
38. The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor
39. An IL 13 coding region variant is associated with, a high total serum IgE level and atopic dermatitis in the German multicenter atopy study (MAS-90)
40. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis
41. Rolipram inhibits staphylococcal enterotoxin B-mediated induction of the human skin-homing receptor on T lymphocytes
42. Clinical and immunologic variables in skin of patients with atopic eczema and either positive or negative atopy patch test reactions
43. Regulation of the high affinity receptor for IgE on human epidermal Langerhans ceLls
44. Activation of human epidermal Langerhans cells by engagement of the high affinity receptor for IgE, Fc epsilon RI
45. IL-4 induces the intracellular expression of the alpha chain of the high-affinity receptor for IgE in in vitro-generated dendritic cells
46. Staphylococcus aureus in the lesions of atopic dermatitis
47. S. aureus isolation from the lesions, the hands, and the anterior nares of patients with atopic dermatitis
48. The case for steroid-antibiotic combinations
49. Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis
50. Evidence for superantigen involvement in skin homing of T cells in atopic dermatitis
51. Evidence for a disease-promoting effect of Staphylococcus aureus-derived exotoxins in atopic dermatitis
52. Prevalence and role of serum IgE antibodies to the Staphylococcus aureusderived superantigens SEA and SEB in children with atopic dermatitis
53. Evaluation of the staphylococcal exotoxins and their specific IgE in childhood atopic dermatitis
54. Induction of corticosteroid insensitivity in human PBMCs by microbial superantigens
55. Application of Staphylococcal enterotoxin B on normal and atopic skin induces up-regulation of T cells by a superantigen-mediated mechanism
56. Bacterial superantigens induce T cell expression of the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen, via stimulation of interleukin 12 production
57. Dose-response in double-blind, placebo-controlled oral food challenges in children with atopic dermatitis
58. T-cell reactivity for a peanut-derived epitope in the skin of a young infant with atopic dermatitis
59. Differences in antigen-specific T-cell responses between infants with atopic dermatitis with and without cow's milk allergy: Relevance of TH2 cytokines
60. Milk-induced eczema is associated with the expansion of T cells expressing cutaneous lymphocyte antigen
61. Association between severity of atopic eczema and degree of sensitization to aeroallergens in schoolchildren
62. Birch pollenrelated foods trigger atopic dermatitis in patients with specific cutaneous T-cell responses to birch pollen antigens
63. Skin-derived aeroallergen-specific T-cell clones of Th2 phenotype in patients with atopic dermatitis
64. The relationship between positive aeroallergen patch test reactions and aeroallergen exacerbations of atopic dermatitis
65. Modulation of the atopy patch test reaction by topical corticosteroids and tar
66. Double-blind controlled trial of effect of house dust-mite allergen avoidance on atopic dermatitis
67. Effectiveness of occlusive bedding in the treatment of atopic dermatitis - A placebo-controlled trial of 12 months' duration
68. Autoallergy: A pathogenetic factor in atopic dermatitis?
69. Autoantibodies to DFS 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions
70. Anti-inflammatory effect of FK-506 on human skin mast cells
71. Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506)
72. Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions
73. Tacrolimus (FK506): New treatment approach in superantigen -associated diseases like atopic dermatitis?